NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News

Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRNB shares have increased by 70.5% and is now trading at $91.89.
View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Principia Biopharma.

Principia Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Principia Biopharma.

Principia Biopharma Inc (NASDAQ:PRNB) announced its quarterly earnings data on Thursday, August, 6th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of ($1.03) by $1.34.
View Principia Biopharma's earnings history.

7 Wall Street analysts have issued 1 year price targets for Principia Biopharma's stock. Their forecasts range from $76.00 to $108.00. On average, they anticipate Principia Biopharma's stock price to reach $87.33 in the next year. This suggests that the stock has a possible downside of 5.0%.
View analysts' price targets for Principia Biopharma.

Media headlines about PRNB stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Principia Biopharma earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Principia Biopharma.

Some companies that are related to Principia Biopharma include Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Reata Pharmaceuticals (RETA) and Ultragenyx Pharmaceutical (RARE).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include AbbVie (ABBV), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Corbus Pharmaceuticals (CRBP) and Five Prime Therapeutics (FPRX).

(PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

Principia Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include First Trust Advisors LP (0.18%), Swiss National Bank (0.17%), Alps Advisors Inc. (0.14%), Candriam Luxembourg S.C.A. (0.13%), New York State Common Retirement Fund (0.08%) and Russell Investments Group Ltd. (0.07%). Company insiders that own Principia Biopharma stock include Alan Colowick, Christopher Y Chai, Daniel J Becker, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Orbimed Advisors Llc, Plc Glaxosmithkline, Roy C Hardiman, Simeon George, Srinivas Akkaraju and Stefani Wolff.
View institutional ownership trends for Principia Biopharma.

PRNB stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Alps Advisors Inc., Candriam Luxembourg S.C.A., Virtus ETF Advisers LLC, SG Americas Securities LLC, and Strs Ohio. Company insiders that have sold Principia Biopharma company stock in the last year include Alan Colowick, Christopher Y Chai, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Roy C Hardiman, and Stefani Wolff.
View insider buying and selling activity for Principia Biopharma.

PRNB stock was purchased by a variety of institutional investors in the last quarter, including Trexquant Investment LP, Rafferty Asset Management LLC, New York State Common Retirement Fund, Swiss National Bank, Principal Financial Group Inc., Russell Investments Group Ltd., Public Employees Retirement Association of Colorado, and State Board of Administration of Florida Retirement System. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George, and Srinivas Akkaraju.
View insider buying and selling activity for Principia Biopharma.

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRNB stock can currently be purchased for approximately $91.89.

Principia Biopharma has a market capitalization of $3.04 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.

The official website for Principia Biopharma is www.principiabio.com.

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]